Ryder

R

Market cap $9.71B

VANCOUVER, BC / ACCESS Newswire / May 29, 2026 / Core Critical Metals Corp. ("CCMC" or the "Company") (TSXV:CCMC)(OTCQB:CCMCF) (WKN: A41G8G), a North American mineral acquisition and exploration company, is pleased to announce that its common shares have been approved for listing on the OTCQB® Venture Market, operated by OTC Markets Group Inc. The Company's shares now trade on the OTCQB under the ticker symbol "CCMCF". In addition, the Company is pleased to confirm that its common shares have achieved Depository Trust Company ("DTC") eligibility, greatly facilitating the electronic clearing and settlement of its shares in the United States.

Theralase(R) Provides an Update on its Phase II Bladder Cancer Clinical Study Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's unaudited interim consolidated financial statements for the three-month period ended March 31st, 2026 ("Financial Statements"). Theralase® will be hosting a conference call on June 9 th at 11:00 am ET, which will include a presentation of the financial and operational results for the quarter ended March 31st, 2026.

R pairs veteran-focused hiring with rising shareholder returns as earnings estimates climb and shares outperform.

UPPSALA, SE / ACCESS Newswire / May 28, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announced new data published in the European Journal of Cancer showing that DiviTumTKa can capture early, treatment-specific biological response in patients with endocrine-resistant HR+/HER2− metastatic breast cancer. The analysis included 555 patients from the phase III GEICAM/2013-02 PEARL trial and used Biovica's FDA 510(k)-cleared DiviTum TKa assay.

VANCOUVER, BC / ACCESS Newswire / May 27, 2026 / Totec Resources Ltd. ("Totec" or the "Company") (TSXV:TOTC)(OTCQB:TTCRF)(FSE:U0Z0), a leading resource company focused on critical metals and supporting the North American supply chain, is pleased to announce that its common shares have been approved for listing on the OTCQB® Venture Market, operated by OTC Markets Group Inc. The Company's shares are expected to commence trading on the OTCQB on May 28, 2026 under the ticker symbol "TTCRF".

The framework centers on site speed, server response, and technical reliability as AI retrieval becomes a filter for citation and discovery. Memphis, Tennessee--(Newsfile Corp. - May 27, 2026) - Leading digital marketing agency HigherVisibility, introduced an updated version of its Targeted Growth System (TGS), a proprietary methodology used across the agency's SEO, PPC, link building, eCommerce SEO, website design, and franchise SEO services.

MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) has been recognized as a 3 Star Employer in the 2026 VETS Indexes Employer Awards, underscoring the company's long‑standing commitment to recruiting, hiring, retaining, developing, and supporting veterans and the military‑connected community. This represents Ryder's second time receiving this honor, following its 2024 designation as a VETS Indexes Recognized Employer. “Ryder is proud to employ so many members of the veteran community and to r.

New York, New York--(Newsfile Corp. - May 25, 2026) - KottonSpa™, a Texas-founded newborn brand that launched in March, introduced a collection of newborn essentials crafted entirely from 100% American-grown SUPIMA® cotton - widely regarded as the world's finest cottons and representing less than 1% of global cotton production. The collection includes SUPIMA® baby accessories, skin-first apparel, and occasion-ready pieces designed for newborns and toddlers ages 0–4 years.

BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by three the historical single agent activity of 8% in KEYNOTE-100 (2019) 56% disease control rate (DCR) in the combination arm, including multiple durable responses extending beyond 10 months with patients still on treatment The treatment exhibits a very favorable safety profile, and, in contrast to chemotherapy-based regimens, result in very low rates of safety-related treatment discontinuations A preliminary median progression-free survival (mPFS) of 10.3 months in the combination arm, based on early PFS analysis Activity observed across both high-grade serous and clear cell ovarian cancer subtypes Demonstrated robust Treg depletion, reprogramming of myeloid cells, and CD8+ T-cell activation, supporting BI-1808's differentiated mechanism and combination synergy with pembrolizumab Cohort expansion is underway, focusing on high-grade serous and clear cell subtypes, with another data readout expected in H2 2026 LUND, SE / ACCESS Newswire / May 21, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced highly promising early data from its ongoing Phase 2a clinical trial evaluating BI-1808, its monoclonal antibody targeting TNFR2, in combination with MSD's (Merck & Co., Inc., Rahway, NJ., USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the treatment of heavily pretreated patients with advanced ovarian cancer.

Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering") of 19,166,667 units ("Units") of the Company at a price of C$0.24 per Unit ("Offering Price") for gross proceeds of C$4,600,000; including, the full exercise of the over-allotment option. The Brokered Offering was led by Research Capital Corporation as sole agent and sole bookrunner ("Agent").